**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 18911**

**Manuscript Type: TOPIC HIGHLIGHTS**

2015 Advances in Hepatitis B virus

**Hepatitis B virus infection in Indonesia**

Yano Y *et al*. Hepatitis B virus

Yoshihiko Yano, Takako Utsumi, Maria Inge Lusida, Yoshitake Hayashi

**Takako Utsumi, Yoshihiko Yano**, **Yoshitake Hayashi**, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan

**Takako Utsumi**, **Maria Inge Lusida**, Indonesia-Japan Collaborative Research Center for Emerging and Re-emerging Infectious Diseases, Institute of Tropical Disease, Airlangga University, Surabaya 60115, Indonesia

**Author contributions:** All the authors made a substantial contribution to the conception and design of the study, data acquisition, and to drafting and critically revising the manuscript; the authors approved the final version.

**Supported by** The Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) program from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

**Conflict-of-interest statement:** All the authors declare that they have no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Takako Utsumi, PhD,** Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. tutsumi@people.kobe-u.ac.jp

**Telephone:** +82-31-5992445

**Fax:** +82-31-5992445

**Received:** April 28, 2015

**Peer-review started:** May 6, 2015

**First decision:** June 26, 2015

**Revised:** July 14, 2015

**Accepted:** September 14, 2015

**Article in press:**

**Published online:**

**Abstract**

Approximately 240 million people are chronically infected with hepatitis B virus (HBV), 75% of whom reside in Asia. Approximately 600000 of infected patients die each year due to HBV-related diseases or hepatocellular carcinoma (HCC). The endemicity of hepatitis surface antigen in Indonesia is intermediate to high with a geographical difference. The risk of HBV infection is high in hemodialysis (HD) patients, men having sex with men, and health care workers. Occult hepatitis B virus infection has been detected in various groups such as blood donors, HD patients, and HIV-infected individuals and children. The most common HBV subgenotype in Indonesia is B3 followed by C1. Various novel subgenotypes of HBV have been identified throughout Indonesia, with the novel HBV subgenotypes C6-C16 and D6 being successfully isolated. Although a number of HBV subgenotypes have been discovered in Indonesia, genotype-related pathogenicity has not yet been elucidated in detail. Therefore, genotype-related differences in the prognosis of liver disease and their effects on treatments need to be determined. A previous study conducted in Indonesia revealed that hepatic steatosis was associated with disease progression. Pre-S2 mutations and mutations at C1638T and T1753V in HBV/B3 have been associated with advanced liver diseases including HCC. However, drug resistance to lamivudine, which is prominent in Indonesia, remains obscure. Although the number of studies on HBV in Indonesia has been increasing, adequate databases on HBV infection are limited. We herein provided an overview of the epidemiology and clinical characteristics of HBV infection in Indonesia.

**Key words:** Hepatitis B virus; Epidemiology; Prevention; Clinical characteristics; Indonesia

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Hepatitis B virus (HBV) infection is an important public concern and its prevalence varies greatly in different parts of the world. The high prevalence of HBV in Indonesia highlights the need to improve prevention and control measures because few evidence-based prevention strategies are currently available. Although studies on HBV in Indonesia are increasing, it is still not fully understood. We herein reviewed epidemiologically important aspects of HBV infection in Indonesia.

Yano Y, Utsumi T, Lusida MI, Hayashi Y. Hepatitis B virus infection in Indonesia. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Hepatitis B virus (HBV) infection is associated with a diverse range of liver damage including asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Approximately 240 million people are chronically infected with HBV[1], 75% of whom reside in Asia[2]. Approximately 600000 of infected patients die each year of HBV-related diseases or HCC[3]. The prevalence of HBV infection varies according to the geographic region, and is categorized as high (≥ 8%), intermediate (2%-7%), or low (< 2%) endemicity. The endemicity of HBV in Indonesia is moderate to high[4,5], ranging from 2.5% to 10% for hepatitis B surface antigen (HBsAg)[2,5,6]. HBV has been classified into at least 9 genotypes (A through H and J) and has been shown to have a distinct geographical distribution[7,8]. The most common HBV subgenotype is HBV B3 (HBV/B3), followed by HBV/C1[9]; however, various novel genotypes have been detected in Indonesia.

Indonesia is the largest archipelago in the world, consisting of five major islands and approximately 30 smaller groups. The archipelago is located between two oceans, the Pacific and Indian oceans, and bridges two continents, Asia and Australia. This strategic position has influenced the serological and virological aspects of HBV infection (Figure 1). Although the number of studies conducted on HBV in Indonesia has increased, adequate databases on HBV infection are still limited[10]. The epidemiology of HBV remains obscure in Indonesia[11]. Therefore, we herein provided an overview of HBV infection among the Indonesian population.

**PREVALENCE OF HBV INFECTION AND RISK FACTORS IN INDONESIA**

The prevalence of chronic HBV infection varies greatly in different areas of the world and the prevalence of chronic HBV infection can be categorized as high, intermediate, or low endemicity. Table 1 shows the prevalence of the HBsAg in not only the general population, but also risk groups such as commercial sex workers (CSW) and men having sex with men (MSM). The prevalence of HBV in the general population in Indonesia is higher than that of HCV (2%)[12], with the highest rates being reported in Makassar (7.1%)[13] in Sulawesi Island and the lowest rates being reported in Jakarta (4.0%)[14] in Java Island; however, another study reported that the prevalence of HBV in Jakarta was 5.8% in the general population[15]. Hasan previously reported that the prevalence of HBV infection in the general population was the highest in Pontianak (9.1%) in the Kalimantan Island[5]. Furthermore, the prevalence of HBsAg was markedly higher in habitants in the highland of Papua (12.8%) and North Sulawesi (33.0%)[16]. The prevalence of HBsAg in pregnant women was found to be the same as that in the general population in Indonesia[17,18]. These findings demonstrated that the endemicity of HBsAg among the general population in Indonesia is intermediate to high, as reported previously[2,19].

HBV infection was not detected in children in Tahuna, North Sulawesi, and Surabaya, East Java, suggesting the efficacy of Hepatitis B (HB) vaccinations in pre-school children[11,20].

The highest risk group of HBV infection was previously reported to be HD patients (11.2%) in Yogyakarta[12], followed by MSM (9.8%)[21] in Solo in the Java Island (Table 1). The prevalence of HBV/HIV co-infection was found to be higher than that of HBV infection alone in Indonesia[22-24] as well as in neighboring countries such as Vietnam and India. The incidence of HIV and HBV burden are currently increasing in Indonesia[22,23,25]; however, no HBV/HIV co-infection cases have been identified in CSW[26]. The prevalence of HBsAg has been classified as high endemicity (8.8%) in health care workers[27] and intermediate endemicity in staff in HDU (5.7%) throughout Indonesia (Table 1). A previous study also revealed that the prevalence of HBsAg was high among medical employees in Padang (11.2%), Mataram (13.3%), and Irian Jaya (13.3%)[5].

Many unique animals exist in Indonesia because of its specific ecosystem. Gibbons in Kalimantan were previously reported to be infected with HBV having their own genotype[28].

**OCCULT HBV INFECTION**

Occult HBV infection (OBI) is defined as the presence of HBV DNA in the serum and/or liver tissue of individuals with HBV core antibodies (anti-HBc) without HBsAg[29]. Several studies have been conducted on OBI in Indonesia. OBI was detected in 8.1% of blood donors with amino acid mutations (T123A, M133L, and T143M) in the *a* determinant of HBsAg, which resulted in changes in predicted antigenicity[30]. Several OBI cases were detected among school children with the variant T126I, which may be one of the viral mechanisms helping the virus to escape from current HB vaccines in Indonesia[31]. In Banjarmasin, Kalimantan, OBI was identified in healthy young adults with 13 amino acid substitutions[32]. Awareness of the reactivation of OBI has increased in Indonesia, especially in HBV endemic areas[33]. A total of 27.1% and 14.7% of HIV-infected individuals and HD patients, respectively, were considered to have OBI[12,22], suggesting that the prevalence of HBV infection regardless of HBsAg was high in immunosuppressive patients.

**HBV GENOTYPES/SUBGENOTYPES IN INDONESIA**

HBV is currently grouped into at least 9 genotypes (A through H and J, with I still being controversial)[34]. The HBV sequence is characterized by more than 8% nucleotide (nt) differences for genotypes and 4%-8% for subgenotypes. The most common HBV subgenotype in Indonesia is HBV/B3, followed by HBV/C1[35,36] (Table 1), with various novel subgenotypes of HBV being identified throughout Indonesia. Ten novel HBV subgenotypes (HBV/C7-C16) were isolated in Indonesia between 2008 and 2012[37-41]. HBV/C6, HBV/C11, and HBV/D6 were identified in a Papuan population[36,40,42]. Genotype J (HBV/J) was detected in a Japanese patient with HCC who was thought to have been infected in Kalimantan, Indonesia, during World War II[28,43]. HBV isolates from subjects from Sulawesi clustered within the HBV/C5, together with known isolates from the Philippinesand Vietnam[11]. The distribution of genotypes/subgenotypes varies even in different regions of a country, which may partly be related to the ethnic origin of the infected patients.

**PREVENTION**

The most significant achievement in the prevention of HB is the implementation of a universal infant vaccination for HB. The HB universal vaccination was introduced in Indonesia in 1997, with the Indonesian government attempting to ensure that every newborn was vaccinated against HBV infection during the first 7 days of life. The immunization project in Lombok decreased the prevalence of HBsAg from 6.2% to 1.4% among children less than 5 years old[44]. In Surabaya and North Sulawesi, the prevalence of HBsAg in preschool children was reported to be 0%[11,20], a result that was attributed to the universal HB vaccination. Although the prevalence of HBsAg among children varies by region, for example, 3.1% in Lamongan in East Java[31] and 4.2% in Papua, the HB vaccination history is obscure. Since the HB vaccination is one of the Expanded Program on Immunization projects being run by the government, communication with the local government is of great importance for better practices.

**CHARACTERISTICS OF CHRONIC HBV INFECTION IN INDONESIA**

Previous studies revealed that the clinical characteristics of chronic HB (CHB) differed among genotypes, and the prognosis of genotype B was better than that of genotype C[45-47]. However, most studies in Asia were conducted in Taiwan, China, Hong Kong, and Japan. The main subgenotype in Indonesia is HBV/B3, which is different from the subgenotypes HBV/B1 and HBV/B2 mainly analyzed in other Asian countries[48]. Furthermore, HBV/C in Indonesia is mainly HBV/C1 in Java and HBV/C6 in Papua, and is different from HBV/C, which is spreading in East Asian countries such as China and Japan[36,42]. Since most clinical studies conducted in Indonesia involved patients with HBV/B, the clinical course of HBV/C in Indonesia currently remains unclear. Although HCC is prevalent in Indonesia, further studies are needed to determine clinical characteristics in relation to the genotypes in Indonesia.

Recent studies revealed that hepatic steatosis was associated with disease progression[49]. Steatosis was identified as an independent risk factor for HCC and the progression of hepatitis was found to be more rapid in HCV patients with steatosis[50,51]. However, a meta-analysis revealed that hepatic steatosis was not related to the clinical course of HBV patients[52]. A previous study reported that hepatic steatosis was more strongly associated with genotype C (37.9%) than with genotype B (24.0%)[53]. Lesmana *et al*[54] examined 179 CHB patients in Jakarta and found the prevalence of hepatic steatosis to be approximately 30%. Obesity is a serious social issue in Indonesia, as in other countries[55]. However, studies on steatosis in Indonesia are still limited, and, as such, further investigations are warranted.

Although the prevalence of HBV and HCV infections in Southeast Asia including Indonesia is high, clinical studies remain limited. Lamivudine, adefovir, and telbivudine, therapeutic drugs for CHB, are currently covered by health insurance in Indonesia. Although drug resistance to lamivudine has not yet been examined, it is common for the cheapest drug, lamivudine, to be prescribed or antiviral therapy to be discontinued due to economic reasons. Therefore, the prevalence of lamivudine-resistant HBV may increase. Telbivudine, which was recently approved in Indonesia, was found to be effective for Indonesian HBV carriers. Sulaiman *et al*[56] reported that HBeAg loss and the seroconversion rate for HBeAg-positive patients were 28.8% and 14.1% at week 52 of telbivudine therapy, respectively. Furthermore, undetectable HBV DNA (PCR negativity) was 51.8% at week 24 and 62.7% at week 52 of this therapy. However, a large-scale study has not yet been conducted on interferon therapy for CHB and, thus, its effectiveness currently remains unknown.

Previous studies revealed a hepatitis virus co-infection among HIV patients. Anggorowati *et al*[23] examined 126 HIV patients in Yogyakarta city and found that 8% had the HBsAg and were considered to be co-infected with HBV. Utsumi *et al*[23] examined 118 HIV patients in Surabaya City, and reported that 15.3% were HBsAg-positive while 27.1% were positive for HBV-DNA regardless of being HBsAg-negative and were considered to have OBI. These findings suggested that HBV co-infection including OBI was frequent among HIV patients and serological examinations were sometimes insufficient for detecting co-infections because of a compromised immune system. Fibriani *et al*[24] recently examined 616 HIV patients in Bandung city in West Java, found HBV co-infection in approximately 7% of these patients, and identified the clinical characteristics of co-infection as being male and having a history of injection drug use.

HBV infection was examined in hemodialysis patients. Rinonce *et al*[12] examined 161 hemodialysis patients in Yogyakarta, and revealed that the prevalence of HBsAg positivity was 11.8% and also that the viral genomes of several strains were identical, suggesting nosocomial infection.

**LIVER CANCER IN RELATION TO HBV IN INDONESIA**

Cancer-related death is a major public health problem in Indonesia and accounts for the seventh largest cause of death. According to the Jakarta Cancer Registry, the ratio of liver cancer between 2005 and 2007 was 1.4 per 100000 (eleventh place) among women and 4.0 per 100,000 (third place) among men[57]. On the other hand, HBV is the most common cause of HCC. Marwoto *et al*[58,59] firstly reported in 1985 that the frequency of HBV among HCC was 67.0%, while Sulaiman showed that it was 47.6%. Wang *et al*[60] examined the epidemiology of HCC in Japan, India, China, and Indonesia, and found that the positive prevalences of the HBsAg and HCV antibody were 21.0% and 40.0% in Indonesian patients with liver cancer, respectively. HBV is a well-known oncogenic virus, and previous studies revealed that the Pre-S mutation, X mutation, and BCP-PC mutation were associated with hepatocarcinogenesis[61,62]. The Pre-S1 deletion, Pre-S2 deletion, T53C mutation were found to be related to HCC at the S domain. Utama *et al*[63] examined the prevalence of the Pre-S2 mutation among 268 HBV carriers in Bantan, and showed it was 2.7%, 18.2%, 40.9%, and 28.6% in asymptomatic carriers, chronic hepatitis, liver cirrhosis, and HCC, respectively, indicating that the Pre-S2 mutation was an independent factor of progressive liver disease. A meta-analysis revealed that the X domain including an A1762T/G1764A double mutant, T1753V, C1653T, G1896A, and G1899A were related to HCC[64]. Heryanto *et al*[35] compared 40 cirrhosis and liver cancer patients with 109 chronic hepatitis patients in Yogyakarta city, and a multivariate analysis identified being older than 45 years old (OR = 2.61, *P =* 0.034), having a C1638T variation (OR = 1074.57, *P =* 0.005), and having a T1753V variation (OR = 6.39, *P =* 0.047) as independent factors participating in disease progression.

**HBV INFECTION AND HOST FACTORS**

Recent technological advances revealed that various kinds of genetic factors are associated with cancers. The genome-wide association study (GWAS) showed that a large number of single nucleotide polymorphisms (SNPs) were related to various kinds of cancers. In case-control and retrospective studies on liver cancers, numerous candidate genes for SNPs were found to be associated with HCC. In 2009, Kamatani *et al*[65] examined 188 Japanese CHB patients and 934 controls and was the first to show that SNPs in the human leukocyte antigen (HLA)-DP region were associated with chronic HBV carriers. The HLA gene is located in 6p21.3 and plays an important role in antigen presentation. Polymorphisms in this region were also identified not only in Japanese patients, but also in Chinese patients[66,67]. In Indonesian populations, several SNPs including rs3135363 in HLA-DR, rs9277535 in HLA-DP, and rs9267665 in a gene-rich HLA class III interval were associated with HB vaccine responses[68]. Host factors are also important for HBV infection and disease progression. Further analyses are needed to confirm these findings.

**CONCLUSION**

The endemicity of HBsAg in Indonesia is intermediate to high with a geographical difference. HD patients, MSM, and health care workers are at high risk of HBV infection. OBI has also been detected in various groups such as blood donors, HD patients, and HIV-infected individuals and children. Appropriate national immunization programs are required in HBV endemic countries such as Indonesia in order to reduce HBV infection. Although a number of HBV subgenotypes have been discovered in Indonesia, genotype-related pathogenicity has not yet been elucidated in detail. Therefore, genotype-related differences in the prognosis of liver disease and their effects on treatments are eagerly awaited.

**REFERENCES**

1 HIV/AIDS Programme. Guidance on prevention of viral hepatitis B and C among people WHO inject drugs. WHO, 2012. Available from: URL: http: //apps.who.int/iris/bitstream/10665/75357/1/9789241504041\_eng.pdf

2 **Merican I**, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnian SS, Leung N, Lesmana L, Phiet PH, Sjalfoellah Noer HM, Sollano J, Sun HS, Xu DZ. Chronic hepatitis B virus infection in Asian countries. *J Gastroenterol Hepatol* 2000; **15**: 1356-1361 [PMID: 11197043]

3 **Abbas Z**, Siddiqui AR. Management of hepatitis B in developing countries. *World J Hepatol* 2011; **3**: 292-299 [PMID: 22216369 DOI: 10.4254/wjh.v3.i12.292]

4 **Fitria L**, Gunardi H, Akib AAP. Influence of hepatitis B immunization to prevent vertical transmission of Hep-B virus in infants born from Hep-B positive mother. *Paediatr Indones* 2010; **50**: 321-325

5 **Hasan I**. Epidemiology of hepatitis B. *Acta Med Indones* 2005; **37**: 231-234 [PMID: 16317222]

6 **Gunardi H**, Zaimi LF, Soedjatmiko AR, Muljono DH. Current prevalence of hepatitis B infection among parturient women in Jakarta, Indonesia. *Acta Med Indones* 2014; **46**: 3-9 [PMID: 24760802]

7 **Norder H**, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. *Intervirology* 2004; **47**: 289-309 [PMID: 15564741]

8 **Locarnini S**, Littlejohn M, Aziz MN, Yuen L. Possible origins and evolution of the hepatitis B virus (HBV). *Semin Cancer Biol* 2013; **23**: 561-575 [PMID: 24013024 DOI: 10.1016/j.semcancer.2013.08.006]

9 **Siburian MD**, Utama A, Dhenni R, Arnelis N, Fanany I, Intan MD, Kurniasih TS, Andriani F, Afadlal S, Julianto EB, Rasman WS, Zubir N, Mathew G. High prevalence of hepatitis B virus genotype C/C1 in the Minangkabau ethnic group in Indonesia. *Virol J* 2013; **10**: 27 [PMID: 23336976 DOI: 10.1186/1743-422X-10-27]

10 **Prasetyo AA**, Dirgahayu P, Sari Y, Hudiyono H, Kageyama S. Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javan prisons, Indonesia. *J Infect Dev Ctries* 2013; **7**: 453-467 [PMID: 23771289 DOI: 10.3855/jidc.2965.]

11 **Achwan WA**, Muttaqin Z, Zakaria E, Depamede SA, Mulyanto S, Tsuda F, Takahashi K, Abe N, Mishiro S. Epidemiology of hepatitis B, C, and E viruses and human immunodeficiency virus infections in Tahuna, Sangihe-Talaud Archipelago, Indonesia. *Intervirology* 2007; **50**: 408-411 [PMID: 18185013 DOI: 10.1159/000112915]

12 **Rinonce HT**, Yano Y, Utsumi T, Heriyanto DS, Anggorowati N, Widasari DI, Lusida MI, Soetjipto H, Hotta H, Hayashi Y. Hepatitis B and C virus infection among hemodialysis patients in Yogyakarta, Indonesia: Prevalence and molecular evidence for nosocomial transmission. *J Med Virol* 2013; **85**: 1348-1361 [PMID: 23919229]

13 **Amirudin R**, Akil H, Akahane Y, Suzuki H. Hepatitis B and C virus infection in Ujung Pandang, Indonesia. *Gastroenterol Jpn* 1991; **26 Suppl 3**: 184-188 [PMID: 1909264]

14 **Akbar N**, Basuki B, Mulyanto DH, Sulaiman A, Noer HM. Ethnicity, socioeconomic status, transfusions and risk of hepatitis B and hepatitis C infection. *J Gastroenterol Hepatol* 1997; **12**: 752-757 [PMID: 9430042]

15 Budihusodo U, Sulaiman HA, Akbar HN, Lesmana LA, Waspodo AS, Noer HM, Akahane Y, Suzuki H. Seroepidemiology of HBV and HCV infection in Jakarta, Indonesia. Gastroenterol Jpn 1991; 26: 196-201

16 **Wolff AP**, Ruys AH, Dolmans WM, Van Loon AM, Pangalila PF. Hepatitis B virus infection in patients with chronic liver disease and healthy controls in north-Sulawesi, Indonesia. *Trop Geogr Med* 1990; **42**: 221-225 [PMID: 2293430]

17 **Reniers J**, Vranckx R, Ngantung W, Sugita E, Meheus A. Prevalence and determinants of hepatitis B virus markers in pregnant women in West Java, Indonesia. *J Trop Med Hyg* 1987; **90**: 249-253 [PMID: 3669127]

18 **Surya IG**, Kornia K, Suwardewa TG, Mulyanto F, Mishiro S. Serological markers of hepatitis B, C, and E viruses and human immunodeficiency virus type-1 infections in pregnant women in Bali, Indonesia. *J Med Virol* 2005; **75**: 499-503 [PMID: 15714491]

19 **Creati M**, Saleh A, Ruff TA, Stewart T, Otto B, Sutanto A, Clements CJ. Implementing the birth dose of hepatitis B vaccine in rural Indonesia. *Vaccine* 2007; **25**: 5985-5993 [PMID: 17604881]

20 Utsumi T, Lusida MI, Yano Y , Purwono PB, Amin M, Soetjipto, Hotta H, Hayashi Y. Progress in the Control of Hepatitis B Virus Infection among Children in Indonesia. J Vaccines Vaccin 2014: 5, 247

21 **Prasetyo AA**, Ariapramuda R, Kindi EA, Dirgahayu P, Sari Y, Dharmawan R, Kageyama S. Men having sex with men in Surakarta, Indonesia: demographics, behavioral characteristics and prevalence of blood borne pathogens. *Southeast Asian J Trop Med Public Health* 2014; **45**: 1032-1047 [PMID: 25507232]

22 **Utsumi T**, Yano Y, Lusida MI, Nasronudin M, Juniastuti H, Hayashi Y. Detection of highly prevalent hepatitis B virus co-infection with HIV in Indonesia. *Hepatol Res* 2013; **43**: 1032-1039 [PMID: 23336705 DOI: 10.1111/hepr.12053]

23 **Anggorowati N**, Yano Y, Heriyanto DS, Rinonce HT, Utsumi T, Mulya DP, Subronto YW, Hayashi Y. Clinical and virological characteristics of hepatitis B or C virus co-infection with HIV in Indonesian patients. *J Med Virol* 2012; **84**: 857-865 [PMID: 22499006 DOI: 10.1002/jmv.23293]

24 **Fibriani A**, Wisaksana R, Alisjahbana B, Indrati A, Schutten M, van Crevel R, van der Ven A, Boucher CA. Hepatitis B virus prevalence, risk factors and genotype distribution in HIV infected patients from West Java, Indonesia. *J Clin Virol* 2014; **59**: 235-241 [PMID: 24529845 DOI: 10.1016/j.jcv.2014.01.012]

25 **Zaw SK**, Tun ST, Thida A, Aung TK, Maung W, Shwe M, Aye MM, Clevenbergh P. Prevalence of hepatitis C and B virus among patients infected with HIV: a cross-sectional analysis of a large HIV care programme in Myanmar. *Trop Doct* 2013; **43**: 113-115 [PMID: 23800421 DOI: 10.1177/0049475513493416]

26 **Kotaki T**, Khairunisa SQ, Sukartiningrum SD, Arfijanto MV, Utsumi T, Normalina I, Handajani R, Widiyanti P, Rusli M, Rahayu RP, Lusida MI, Hayashi Y, Nasronudin M. High prevalence of HIV-1 CRF01\_AE viruses among female commercial sex workers residing in Surabaya, Indonesia. *PLoS One* 2013; **8**: e82645 [PMID: 24367533 DOI: 10.1371/journal.pone.0082645]

27 **Agustian D**, Yusnita S, Susanto H, Sukandar H, de Schryver A, Meheus A. An estimation of the occupational risk of HBV, HCV and HIV infection among Indonesian health-care workers. *Acta Med Indones* 2009; **41 Suppl 1**: 33-37 [PMID: 19920296]

28 **Utsumi T**, Wahyuni RM, Lusida MI, Yano Y, Priambada NP, Amin M, Purwono PB, Istimagfiroh A, Soetjipto A, Hotta H, Hayashi Y. Full genome characterization and phylogenetic analysis of hepatitis B virus in gibbons and a caretaker in Central Kalimantan, Indonesia. *Arch Virol* 2015; **160**: 685-692 [PMID: 25559671 DOI: 10.1007/s00705-014-2323-9]

29 **Hu KQ**. Occult hepatitis B virus infection and its clinical implications. *J Viral Hepat* 2002; **9**: 243-257 [PMID: 12081601]

30 **Thedja MD**, Roni M, Harahap AR, Siregar NC, Ie SI, Muljono DH. Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein. *Hepatol Int* 2010; **4**: 608-614 [PMID: 21063484 DOI: 10.1007/s12072-010-9203-5]

31 **Utsumi T**, Yano Y, Lusida MI, Amin M, Soetjipto H, Hayashi Y. Serologic and molecular characteristics of hepatitis B virus among school children in East Java, Indonesia. *Am J Trop Med Hyg* 2010; **83**: 189-193 [PMID: 20595500 DOI: 10.4269/ajtmh.2010.09-0589]

32 **Darmawan E**, Turyadi KE, Nursanty NK, Thedja MD, Muljono DH. Seroepidemiology and occult hepatitis B virus infection in young adults in Banjarmasin, Indonesia. *J Med Virol* 2015; **87**: 199-207 [PMID: 25521058 DOI: 10.1002/jmv.24045]

33 **Wijaya I**, Hasan I. Reactivation of hepatitis B virus associated with chemotherapy and immunosuppressive agent. *Acta Med Indones* 2013; **45**: 61-66 [PMID: 23585411]

34 **Utsumi T**, Yano Y, Hotta H. Molecular epidemiology of hepatitis B virus in Asia. *World J Med Gene*t 2014; **4**: 19-26 [DOI: 10.5496/wjmg.v4.i2.19]

35 **Heriyanto DS**, Yano Y, Utsumi T, Anggorowati N, Rinonce HT, Lusida MI, Soetjipto C, Ratnasari N, Maduseno S, Purnama PB, Nurdjanah S, Hayashi Y. Mutations within enhancer II and BCP regions of hepatitis B virus in relation to advanced liver diseases in patients infected with subgenotype B3 in Indonesia. *J Med Virol* 2012; **84**: 44-51 [PMID: 22095534 DOI: 10.1002/jmv.22266]

36 **Lusida MI**, Nugrahaputra VE, Soetjipto R, Nagano-Fujii M, Sasayama M, Utsumi T, Hotta H. Novel subgenotypes of hepatitis B virus genotypes C and D in Papua, Indonesia. *J Clin Microbiol* 2008; **46**: 2160-2166 [PMID: 18463220 DOI: 10.1128/JCM.01681-07]

37 **Mulyanto SN**, Surayah K, Tsuda F, Ichiyama K, Takahashi M, Okamoto H. A nationwide molecular epidemiological study on hepatitis B virus in Indonesia: identification of two novel subgenotypes, B8 and C7. *Arch Virol* 2009; **154**: 1047-1059 [PMID: 19499283 DOI: 10.1007/s00705-009-0406-9]

38 **Mulyanto SN**, Surayah K, Tjahyono AA, Jirintai S, Takahashi M, Okamoto H. Identification and characterization of novel hepatitis B virus subgenotype C10 in Nusa Tenggara, Indonesia. *Arch Virol* 2010; **155**: 705-715 [PMID: 20306210 DOI: 10.1007/s00705-010-0628-x]

39 **Mulyanto SN**, Wahyono A, Jirintai S, Takahashi M, Okamoto H. Analysis of the full-length genomes of novel hepatitis B virus subgenotypes C11 and C12 in Papua, Indonesia. *J Med Virol* 2011; **83**: 54-64 [PMID: 21108339 DOI: 10.1002/jmv.21931]

40 **Utsumi T**, Nugrahaputra VE, Amin M, Hayashi Y, Hotta H, Lusida MI. Another novel subgenotype of hepatitis B virus genotype C from papuans of Highland origin. *J Med Virol* 2011; **83**: 225-234 [PMID: 21181916 DOI: 10.1002/jmv.21963]

41 **Mulyanto P**, Depamede SN, Wahyono A, Jirintai S, Nagashima S, Takahashi M, Nishizawa T, Okamoto H. Identification of four novel subgenotypes (C13-C16) and two inter-genotypic recombinants (C12/G and C13/B3) of hepatitis B virus in Papua province, Indonesia. *Virus Res* 2012; **163**: 129-140 [PMID: 21925554 DOI: 10.1016/j.virusres.2011.09.002]

42 **Utsumi T**, Lusida MI, Yano Y, Nugrahaputra VE, Amin M, Juniastuti Y, Hotta H. Complete genome sequence and phylogenetic relatedness of hepatitis B virus isolates in Papua, Indonesia. *J Clin Microbiol* 2009; **47**: 1842-1847 [PMID: 19386834 DOI: 10.1128/JCM.02328-08]

43 **Tatematsu K**, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, Nakayoshi T, Wakuta M, Miyakawa Y, Mizokami M. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. *J Virol* 2009; **83**: 10538-10547 [PMID: 19640977 DOI: 10.1128/JVI.00462-09]

44 **Ruff TA**, Gertig DM, Otto BF, Gust ID, Sutanto A, Soewarso TI, Kandun N, Marschner IC, Maynard JE. Lombok Hepatitis B Model Immunization Project: toward universal infant hepatitis B immunization in Indonesia. *J Infect Dis* 1995; **171**: 290-296 [PMID: 7844364]

45 **Lee CM**, Chen CH, Lu SN, Tung HD, Chou WJ, Wang JH, Chen TM, Hung CH, Huang CC, Chen WJ. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. *Scand J Gastroenterol* 2003; **38**: 95-101 [PMID: 12608471]

46 **Orito E**, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. *Hepatology* 2001; **33**: 218-223 [PMID: 11124839]

47 **Zhang AM**, Wang HF, Wang HB, Hu JH, He WP, Su HB, Chen J, Du N, Duan XZ. [Association between HBV genotype and chronic/severe liver disease with HBV infection in Chinese patients]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* 2010; **24**: 178-180 [PMID: 21186519]

48 **Utama A**, Purwantomo S, Siburian MD, Dhenni R, Gani RA, Hasan I, Sanityoso A, Miskad UA, Akil F, Yusuf I, Achwan WA, Soemohardjo S, Lelosutan SA, Martamala R, Lukito B, Budihusodo U, Lesmana LA, Sulaiman A, Tai S. Hepatitis B virus subgenotypes and basal core promoter mutations in Indonesia. *World J Gastroenterol* 2009; **15**: 4028-4036 [PMID: 19705499]

49 **Petta S**, Cammà C, Di Marco V, Macaluso FS, Maida M, Pizzolanti G, Belmonte B, Cabibi D, Di Stefano R, Ferraro D, Guarnotta C, Venezia G, Craxì A. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. *Liver Int* 2011; **31**: 507-515 [PMID: 21382161 DOI: 10.1111/j.1478-3231.2011.02453.x]

50 **Koike K**. Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. *J Gastroenterol* 2009; **44 Suppl 19**: 82-88 [PMID: 19148799 DOI: 10.1007/s00535-008-2276-4]

51 **Takuma Y**, Nouso K, Makino Y, Saito S, Takayama H, Takahara M, Takahashi H, Murakami I, Takeuchi H. Hepatic steatosis correlates with the postoperative recurrence of hepatitis C virus-associated hepatocellular carcinoma. *Liver Int* 2007; **27**: 620-626 [PMID: 17498246]

52 [**Machado MV**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Machado%20MV%5BAuthor%5D&cauthor=true&cauthor_uid=21649726), [Oliveira AG](http://www.ncbi.nlm.nih.gov/pubmed/?term=Oliveira%20AG%5BAuthor%5D&cauthor=true&cauthor_uid=21649726), [Cortez-Pinto H](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cortez-Pinto%20H%5BAuthor%5D&cauthor=true&cauthor_uid=21649726). Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients.[*J Gastroenterol Hepatol*](http://www.ncbi.nlm.nih.gov/pubmed/21649726) 2011; **26**: 1361-1367 [PMID: 21649726 DOI: 10.1111/j.1440-1746.2011.06801.x]

53 **Lin CL**, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. *J Gastroenterol Hepatol* 2011; **26 Suppl 1**: 123-130 [PMID: 21199523]

54 **Lesmana LA**, Lesmana CR, Pakasi LS, Krisnuhoni E. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. *Acta Med Indones* 2012; **44**: 35-39 [PMID: 22451183]

55 **Roemling C**, Qaim M. Obesity trends and determinants in Indonesia. *Appetite* 2012; **58**: 1005-1013 [PMID: 22402303 DOI: 10.1016/j.appet.2012.02.053]

56 **Sulaiman A**, Lesmana LA. An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B. *Acta Med Indones* 2014; **46**: 38-43 [PMID: 24760807]

57 **Wahidin M**, Noviani R, Hermawan S, Andriani V, Ardian A, Djarir H. Population-based cancer registration in Indonesia. *Asian Pac J Cancer Prev* 2012; **13**: 1709-1710 [PMID: 22799393]

58 **Sulaiman HA**. Hepatitis B virus infection in liver cirrhosis and hepatocellular carcinoma in Jakarta Indonesia. *Gastroenterol Jpn* 1989; **24**: 434-441 [PMID: 2550307]

59 **Marwoto W**, Diana S, Roostini ES. Epidemiology of liver cancer in Indonesia. *Southeast Asian J Trop Med Public Health* 1985; **16**: 607-608 [PMID: 3012789]

60 **Wang BE**, Ma WM, Sulaiman A, Noer S, Sumoharjo S, Sumarsidi D, Tandon BN, Nakao K, Mishiro S, Miyakawa Y, Akahane Y, Suzuki H. Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries. *J Med Virol* 2002; **67**: 394-400 [PMID: 12116033]

61 **Qu LS**, Liu JX, Liu TT, Shen XZ, Chen TY, Ni ZP, Lu CH. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. *PLoS One* 2014; **9**: e98257 [PMID: 24849936 DOI: 10.1371/journal.pone.0098257]

62 **Liao Y**, Hu X, Chen J, Cai B, Tang J, Ying B, Wang H, Wang L. Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. *PLoS One* 2012; **7**: e38394 [PMID: 22675557 DOI: 10.1371/journal.pone.0038394]

63 **Utama A**, Siburian MD, Fanany I, Intan MD, Dhenni R, Kurniasih TS, Lelosutan SA, Achwan WA, Zubir N, Arnelis B, Yusuf I, Lesmana LA, Sulaiman A. Hepatitis B virus pre-S2 start codon mutations in Indonesian liver disease patients. *World J Gastroenterol* 2012; **18**: 5418-5426 [PMID: 23082059 DOI: 10.3748/wjg.v18.i38.5418]

64 **Liu S**, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. *J Natl Cancer Inst* 2009; **101**: 1066-1082 [PMID: 19574418 DOI: 10.1093/jnci/djp180]

65 **Kamatani Y**, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, Tsunoda T, Kamatani N, Kumada H, Puseenam A, Sura T, Daigo Y, Chayama K, Chantratita W, Nakamura Y, Matsuda K. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. *Nat Genet* 2009; **41**: 591-595 [PMID: 19349983 DOI: 10.1038/ng.348]

66 **Guo X**, Zhang Y, Li J, Ma J, Wei Z, Tan W, O'Brien SJ. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. *Hepatology* 2011; **53**: 422-428 [PMID: 21274863 DOI: 10.1002/hep.24048]

67 **Hu L**, Zhai X, Liu J, Chu M, Pan S, Jiang J, Zhang Y, Wang H, Chen J, Shen H, Hu Z. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. *Hepatology* 2012; **55**: 1426-1431 [PMID: 22105689 DOI: 10.1002/hep.24799]

68 **Png E**, Thalamuthu A, Ong RT, Snippe H, Boland GJ, Seielstad M. A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region. *Hum Mol Genet* 2011; **20**: 3893-3898 [PMID: 21764829 DOI: 10.1093/hmg/ddr302]

**P-Reviewer:** Blum HE, Chen RF **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Java**

**Sumatra**

**Kalimantan**

**Papua**

**Sulawesi**

**Figure 1** **Map of Indonesia.** Indonesia is the largest archipelago in the world, consisting of five major islands and approximately 30 smaller groups.

**Table 1 Prevalence of hepatitis B surface antigen and risk factors in Indonesian populations**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Region** | **Prevalence (%)** | **Subject** | **Main genotype** | **Ref.** |
| Java  |  |  |  |  |
| Bandung | 4.7 | Pregnant women |  | Reniers *et al*[17], 1987 |
| Jakarta | 4.0 | General population |  | Akbar *et al*[14], 1997 |
| Jakarta | 5.8 | General population |  | Budihusodo *et al*[15], 1991 |
| Jakarta | 2.2 | Parturient women |  | Gunardi *et al*[6], 2014 |
| Surabaya | 4.0 | CSW |  | Kotaki *et al*[26], 2013 |
| Solo | 9.8 | MSM |  | Prasetyo *et al*[17], 2014 |
| Four prisons in Central Java1  | 3.2 | Drug abuser inmates in prisons | B3, C1 | Prasetyo *et al*[10], 2013 |
| Yogyakarta | 11.25.7 | HD patientsStaff in HDU | B3B3 | Rinonce *et al*[12], 2013 |
| Sumatra |  |  |  |  |
| Padang |  | HBV carriers | C1, B3 | Siburian *et al*[9], 2013 |
| Kalimantan |  |  |  |  |
| Banjarmasin | 4.6 | General population | B, C | Darmawan *et al*[32]*,* 2015 |
| Sulawesi |  |  |  |  |
| Tahuna | 4.9 | General population | C5 | Achwan *et al*[11], 2007 |
| Makassar | 7.1 | General population |  | Amirudin R *et al*[13], 1991 |
| Bali1 |  |  |  |  |
|  | 1.9 | Pregnant women |  | Surya *et al*[18], 2005 |
| Papua |  |  |  |  |
| Jayapura | 4.6 | General population | C6, D6, B3 | Lusida *et al*[36], 2008 |

1Exact place is not mentioned. MSM: Men having sex with men; CSW: Commercial sex workers; HD: Hemodialysis; HDU: Hemodialysis unit.